^
    Back
    Association details:
    Biomarker:EML4-ALK fusion
    Cancer:Lung Non-Small Cell Squamous Cancer
    Drug:Alunbrig (brigatinib) (EGFR inhibitor, ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Onco Targets Ther
    Title:

    Acquired ALK Resistance Mutations Identified from Liquid Biopsy in an ALK-Rearranged Squamous Cell Lung Cancer Patient Treated with Sequential ALK TKI Therapy: A Case Report

    Published date:
    08/03/2021
    Excerpt:
    NGS revealed an EML4-ALK fusion (E6:A20) with a mutation allelic frequency (MAF) of 0.1% in the patient’s plasma ctDNA...The patient was then switched from crizotinib to brigatinib at a dose of 90 mg in the first week and 180 mg thereafter. The patient achieved a complete response (CR) for the lung lesion and a PR for the brain lesions...
    DOI:
    https://doi.org/10.2147/OTT.S315832